How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study ID
NCT07573449
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [14C]-JNT-517 — DRUG
    Suspension

Study Details

The purpose of this study is to determine the absorption, metabolism and excretion of \[14C\]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Key Dates

Start date
Jan 22, 2024
Status verified
Apr 2026
Primary completion
Jan 22, 2025
Completion
Feb 27, 2025

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: [14C]-JNT-517
    Participants receive a single dose of \[14C\]-JNT-517, orally, on Day 1

Primary Outcome Measure

Total Radioactivity Recovery (fet1-t2) in Urine and Feces [ Time Frame: Up to Day 9 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc.MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc.· Madison, WI

Related Studies